PatientsVille.com Logo

MYOCARDIAL INFARCTION and Naproxen

PatientsVille

MYOCARDIAL INFARCTION Symptoms and Causes

Each year over a million people in the U.S. have a heart attack. About half of them die. Many people have permanent heart damage or die because they don't get help immediately. It's important to know the symptoms of a heart attack and call 9-1-1 if someone is having them. Those symptoms include

  • Chest discomfort - pressure, squeezing, or pain
  • Shortness of breath
  • Discomfort in the upper body - arms, shoulder, neck, back
  • Nausea, vomiting, dizziness, lightheadedness, sweating

These symptoms can sometimes be different in women.

What exactly is a heart attack? Most heart attacks happen when a clot in the coronary artery blocks the supply of blood and oxygen to the heart. Often this leads to an irregular heartbeat - called an arrhythmia - that causes a severe decrease in the pumping function of the heart. A blockage that is not treated within a few hours causes the affected heart muscle to die.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for MYOCARDIAL INFARCTION

MYOCARDIAL INFARCTION treatment research studies

Naproxen clinical trials, surveys and public health registries


Find Drug Side Effect reports



Naproxen Side Effects

Nausea (228)
Gastrointestinal Haemorrhage (220)
Pain (197)
Renal Failure Acute (196)
Dyspnoea (187)
Haemoglobin Decreased (171)
Completed Suicide (169)
Vomiting (162)
Dizziness (156)
Diarrhoea (155)
Gastric Ulcer (153)
Abdominal Pain (149)
Haematemesis (145)
Gastric Haemorrhage (137)
Duodenal Ulcer (122)
Abdominal Pain Upper (118)
Chest Pain (118)
Pruritus (118)
Anaemia (109)
Arthralgia (103)
Asthenia (65)
Pulmonary Embolism (64)
Rash (63)
No Adverse Event (63)
Melaena (63)
Upper Gastrointestinal Haemorrhage (62)
Headache (62)
Malaise (61)
Oedema Peripheral (58)
Deep Vein Thrombosis (58)
Urticaria (57)
Hypersensitivity (56)
Toxicity To Various Agents (56)
Anxiety (55)
Pyrexia (53)
Fatigue (50)
Faeces Discoloured (50)
Back Pain (49)
Cardiac Arrest (49)
Pain In Extremity (47)
Cholelithiasis (46)
Hypotension (45)
Overdose (44)
Injury (44)
Swelling Face (43)
Gastritis (42)
Feeling Abnormal (42)
Angioedema (42)
Depression (41)
Blood Creatinine Increased (39)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

MYOCARDIAL INFARCTION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Precancerous Condition
Interventions: Drug: Naproxen;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Change in PGE2 concentration levels in normal colorectal mucosa;   Minimal biologically effective dose of Naproxen defined by modulation of PGE2 levels;   Response defined as >= 30% reduction in PGE2 levels;   Incidence of toxicity graded according to National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) version 4.0;   Naproxen concentrations in plasma samples;   Naproxen concentrations in normal colorectal mucosa;   PGE-M levels in urine samples;   Change in number of polyps observed in the rectosigmoid area;   Changes in the microRNA profile of the normal colorectal mucosa;   Changes in gene expression mRNA profiles of the normal colorectal mucosa;   Changes in the mutational rate of the normal colorectal mucosa
2 Unknown  Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Condition: Osteoarthritis, Knee
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Efficacy of Naproxen vs. placebo;   Safety
3 Not yet recruiting Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Conditions: Migraine;   Headache
Interventions: Drug: naratriptan + Naproxen;   Drug: naratriptan;   Drug: Naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication;   Headache relief 4 hours after dosing, without use of rescue medication;   Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Maintenance of pain-free response between 2 and 24 hours, without use of rescue medication;   Freedom from nausea, vomiting, photophobia and phonophobia 2 and 4 hours after dosing;   Maintenance of freedom from nausea, vomiting, photophobia and phonophobia between 2 and 24 hours after dosing, without use of rescue medication;   Recurrence of pain between 2 and 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
4 Unknown  Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Conditions: Migraine;   Headache
Interventions: Drug: Fixed-dose combination of naratriptan + Naproxen;   Drug: Naratriptan;   Drug: Naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication.;   Headache relief 4 hours after dosing, without use of rescue medication;   Sustained headache relief over 24 hours, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Sustained pain-free response over 24 hours, without use of rescue medication;   Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication;   Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
5 Recruiting Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Conditions: Arthritis;   Cardiovascular Diseases;   Cerebrovascular Disorders
Interventions: Drug: Celecoxib(drug);   Drug: Naproxen(drug)
Outcome Measures: Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria;   Cardiovascular events
6 Recruiting NOLAN: Naproxen or Loratadine and Neulasta
Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen;   Drug: Loratadine
Outcome Measures: Bone pain (all grade) in cycle 1;   Bone pain (all grade) by cycle (2-4) and across cycles;   Severe (grade 3/4) bone pain by cycle and across cycles;   Subject reported bone pain;   Maximum Subject Reported bone pain;   Area under the Curve for subject-reported bone pain;   Adverse Event and Serious Adverse Events;   Severity of Adverse Events
7 Unknown  Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial
Condition: Pain, Postoperative
Interventions: Drug: Naproxen;   Drug: placebo
Outcome Measures: cumulative opiate dose administered, as recorded on the computerized medication administration record (CMAR);   patient reported pain scores;   side effects of study medication and opiate analgesia
8 Recruiting The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
Conditions: Pleural Effusion;   Pleural Effusion Malignant
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Change in volume of pleural effusion collected;   Hospital length of stay; compared between intervention and control arms;   Gastrointestinal complications;   General re-admission rates;   Total number of days chest tubes remain in-situ
9 Recruiting Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Condition: Arthritis, Rheumatoid
Interventions: Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Outcome Measures: The first occurrence of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, or non-fatal stroke (APTC composite endpoint).;   The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs);   Patient's Assessment of Arthritis Pain (VAS);   The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
10 Not yet recruiting Effect of L-dopa In Subacute Back Pain Population
Condition: Sub-acute Back Pain
Interventions: Drug: Naproxen;   Drug: Carbidopa/Levodopa;   Drug: Placebo
Outcome Measure: VAS pain scale
11 Not yet recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
Outcome Measure: Change in pain intensity
12 Not yet recruiting Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
Condition: Acute Pain
Interventions: Drug: Naproxen;   Drug: Sinemet;   Drug: Placebo
Outcome Measure: VAS pain scale
13 Recruiting Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
Condition: Migraine With Aura
Interventions: Drug: sumatriptan with naprosyn;   Drug: placebo
Outcome Measures: Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).;   Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.
14 Recruiting A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis (JIA)
Interventions: Drug: VIMOVO 250/20;   Drug: VIMOVO 375/20;   Drug: VIMOVO 500/20
Outcome Measures: Incidence of severity of AEs and SAEs.;   Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.;   Change from baseline in vital signs, physical examination results and clinical laboratory tests.;   Pharmacokinetic (PK) in terms of characteristics of VIMOVO (Naproxen / esomeprazole).
15 Not yet recruiting Placebo In Chronic Pain
Condition: Chronic Back Pain
Interventions: Drug: Naproxen;   Drug: Placebo;   Drug: Omeprazole
Outcome Measure: VAS pain scale
16 Recruiting Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
Condition: TMD
Interventions: Radiation: low level laser therapy;   Drug: Naproxen
Outcome Measure: reduction of paim measured by VAS
17 Recruiting Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analog Scale (VAS).;   Safety will be evaluated by the adverse events occurrences
18 Not yet recruiting Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).;   Safety will be evaluated by the adverse events occurrences
19 Recruiting A Randomized Study of Three Medication Regimens for Acute Low Back Pain
Condition: Acute Low Back Pain
Interventions: Drug: Naproxen;   Drug: Cyclobenzaprine;   Drug: Oxycodone/ acetaminophen
Outcome Measure: Roland Morris low back pain functional disability scale
20 Unknown  Ictal and Interictal Inflammatory Markers in Migraine
Condition: Migraine
Interventions: Drug: sumatriptan/Naproxen sodium;   Drug: Placebo
Outcome Measure: Blood levels of proteins will be evaluated at baseline when subjects are pain-free and then repeated during an acute attack, both prior to drug administration and then at 30 minutes, 1 hour and 2 hours after acute treatment.